The first product will target rheumatoid arthritis with the potential to help in diagnosis and disease management.

Advanced Proteome Therapeutics (APT) and Atreus Pharmaceuticals are exploring the development of protein-in vivo imaging agents. The collaboration will use APT’s advanced site-directed peptide modification techniques.

The first product is intended for imaging the earliest changes associated with rheumatoid arthritis. The resulting technology is expected to have clinical applications in the diagnosis and management of early rheumatoid arthritis.

Under the agreement, Atreus will have the exclusive right to commercialize the jointly developed agents in return for revenue-sharing payments to APT. Atreus will provide technical, clinical, and market expertise to the program as well as intellectual property rights.

Previous articleSeparate Studies Found Two Rheumatoid Arthritis Related SNPs in the Same Region
Next articleCenomed Coawarded Chemical Defense Grant